THROMBOTIC MICROANGIOPATHY. Jun-Ki Park 7/19/11

Size: px
Start display at page:

Download "THROMBOTIC MICROANGIOPATHY. Jun-Ki Park 7/19/11"

Transcription

1 THROMBOTIC MICROANGIOPATHY Jun-Ki Park 7/19/11

2 TMAs are microvascular occlusive disorders characterized by systemic or intrarenal aggregation of platelets, thrombocytopenia, and mechanical injury to erythrocytes. TMA is a descriptive name for the histologic abnormalities: - Thrombi in the glomeruli and arterioles. - EM: subendothelial widening of the glomerular capillary wall due to the deposition of fibrin-like material. - During healing, mucoid intimal thickening and then onion-skin hypertrophy of the interlobular arteries.

3 In addition to TTP and HUS, TMA may occur in other disorders, such as: - malignant HTN - scleroderma - anti-phopholipid antibody syndrome -SLE - preeclampsia - radiation nephropathy - renal allograft rejection - HIV infection - allogenic HSCT - disseminated malignancy

4 History Thrombotic thrombocytopenic purpura (TTP) Moschowitz described in 1924 as a new disease characterized by unique pathological findings of hyaline thrombi in many organs. Amorosi and Ultmann defined in 1964 the classic clinical features: - Thrombocytopenia - MAHA - neurologic symptoms - renal dysfunction - fever Hemolytic-uremic syndrome (HUS) First described by Gasser et al. in 1955 in a report of five children with acute renal failure who died with renal cortical necrosis. Current childhood HUS is a different disorder, noticed since 1980 with the appearance of Shiga toxin-producing Escherichia coli (usually E. coli O157:H7, most recent outbreak of O104:H4 )

5 Incidence D. R. TERRELL et al. Journal of Thrombosis and Haemostasis, 3: , 2005

6 For the 206 patients with an initial episode of clinically suspected TTP-HUS in whom the decision to initiate plasma exchange treatment was made, the clinical setting in which these patients presented included the following: Idiopathic 37 percent Drug-associated 13 percent Autoimmune disease 13 percent Infection 9 percent Pregnancy/postpartum 7 percent Bloody diarrhea prodrome 6 percent Hematopoietic cell transplantation 4 percent D. R. TERRELL et al. Journal of Thrombosis and Haemostasis, 3: , 2005

7 Definitions - TTP TTP: A syndrome of MAHA, thrombocytopenia with or without renal or neurologic abnormalities, without another etiology, such as systemic infection or another cause of TMA. Diagnosis of TTP requires treatment with PLEX. Congenital TTP (Upshaw-Schulman Syndrome): A rare syndrome caused by congenital ADAMTS13 deficiency, may occur at any age. Treatment with plasma infusion sufficient.

8 Definitions - HUS Typical HUS: A syndrome of MAHA, thrombocytopenia and renal failure with a diarrhea prodrome caused by infection with Shiga toxin-producing bacteria. Primarily in children < 5yrs, ~90-95% if childhood HUS. E.coli O157:H7 most common etiology; most recent outbreak of HUS in Germany d/t serotype O104:H4 Occurs most frequently in children under 5 years with an incidence of 6.1 per , as compared with overall incidence of 1-2 cases per Atypical HUS: A syndrome of MAHA, thrombocytopenia and renal failure without a diarrheal prodrome. Primarily in children < 5yrs, 5-10% of childhood HUS; abnormalities of complements regulation may be the most common etiology.

9 Pathophysiology - TTP Monomers of vwf (280kD) are linked by disulfide bonds to form multimers ranging into millions of daltons. Multimeres of vwf are constructed within megakaryocytes and endothelial cells; stored within platelet alpha-granules and endothelial Weibel-Palade bodies. ADAMTS13 (vwf cleaving metalloprotesase) in plasma normally prevents the persistence of large multimers of vwf (ULVWF) and its entry in to circulation. Mutations in the gene for ADAMTS13 leads to familial TTP, acquired TTP usually characterized by presence of Auto-Abs against ADAMTS13.

10 Joel L. Moake NEJM 2002

11 Normal plasma contains VWF-cleaving activity JF Dong, Blood 2002

12 Cleavage of the ULVWF strings with adherent platelets by normal plasma, TTP plasma, or ADAMTS-13. JF Dong, Blood 2002

13 Plasma from patients with TTP did not cleave the ULVWF strings with adherent platelets JF Dong, Blood 2002

14 Effect of TTP plasma on the ULVWF-cleaving activity of ADAMTS-13 JF Dong, Blood 2002

15 Effect of TTP plasma on the ULVWF-cleaving activity of ADAMTS-13. Summary of multiple sample analyses. Results expressed as means SEM, n 3 JF Dong, Blood 2002

16 Gerorge JN, Blood 116 (20): , 2010

17 Joel L. Moake NEJM 2002

18 Joel L. Moake NEJM 2002

19 Pathogenetic Scheme of Atypical HUS H-M Tsai, Kidney International (2006) 70, 16-23

20 Plasma Exchange vs Plasma Infusion Rock GA et al. NEJM 1991; 325:392-7

21 Rock GA et al. NEJM 1991; 325:392-7

22 A companion study reported outcomes of 24 pts with oliguric renal failure who were excluded from the randomized trial because they could not be assigned to plasma infusion group because of risk of volume overload. The survival of these 24 pts treated with PLEX was 83%. (Rock GA et al. Transfusion 2002) These observations document that PLEX is beneficial for patients who meet the diagnostic criteria for TTP with or without renal failure.

23 Exceptions to General Recommendation of PLEX in TTP-HUS Secondary to HSCT or cancer treatment: From 23 Pts with clinical features of TTP after allogeneic HSCT who received PLEX, 22 died. Autopsies showed that systemic infection were the most common cause of death and demonstrated no e/o systemic microvascular thrombosis. These pts had renal TMA. Acute versus host disease was usual etiologies for MAHA and thrombocytopenia. To avoid unnecessary PLEX, the name of this syndrome has been changed to HSCT-associated TMA. There are only sporadical and anecdotal reports that suggest efficacy of PLEX for chemotherapy induced TTP-HUS (e.g. gemcitabine) George JN, Blood 116 (20): , 2010

24 Exceptions to General Recommendation of PLEX in TTP-HUS Post-diarrheal HUS in children The typical diarrhea-associated HUS of young children, most often caused by enteric infection by E. coli O157:H7, usually resolves spontaneously, following supportive therapy alone. PLEX may be considered in patients with severe neurologic abnormalities or persistent disease.

25 Gerorge JN, Blood 116 (20): , 2010

26 Athrombocytopenic Thrombotic Microangiopathy 30 yr retrospective cohort who underwent kidney biopsies before 2007 and were found to have intimal proliferaton and/or endothelial swelling with luminal fibrin deposition in arterial or capillary beds but no signs of vasculitis, acute rejections or extensive microthrombosis. De Serres and Isenring, NDT (2009) 24:

27 Athrombocytopenic Thrombotic Microangiopathy De Serres and Isenring, NDT (2009) 24:

28 De Serres and Isenring, NDT (2009) 24:

29 Athrombocytopenic Thrombotic Microangiopathy TMA lesions could present with normal PLT and lead to substantial renal damage quite commonly. These observations raise the concern that athrombocytopenic TMA may not be considered for timely therapeutic interventions based on current diagnostic criteria or because of delayed identification Prospective trials aimed at determining the usefulness of plasmapheresis in atypical forms of TMA needed.

30 THANK YOU!

A 23 year old Caucasian male presented with shortness of breath, hypertension, bloody sputum, and a history of drug abuse (confirmed by urinalysis).

A 23 year old Caucasian male presented with shortness of breath, hypertension, bloody sputum, and a history of drug abuse (confirmed by urinalysis). A 23 year old Caucasian male presented with shortness of breath, hypertension, bloody sputum, and a history of drug abuse (confirmed by urinalysis). He was found to have severe kidney injury requiring

More information

Some renal vascular disorders

Some renal vascular disorders Some renal vascular disorders Introduction Nearly all diseases of the kidney involve the renal blood vessels secondarily We will discuss: -Hypertension (arterionephrosclerosis in benign HTN & hyperplastic

More information

New insights in thrombotic microangiopathies : TTP and ahus

New insights in thrombotic microangiopathies : TTP and ahus New insights in thrombotic microangiopathies : TTP and ahus Dr Catherine LAMBERT Hematology Cliniques universitaires Saint-Luc Catherine.lambert@uclouvain.be New insights in thrombotic microangiopathies

More information

Thrombotic Thrombocytopenic Purpura and the Role of ADAMTS-13

Thrombotic Thrombocytopenic Purpura and the Role of ADAMTS-13 Thrombotic Thrombocytopenic Purpura and the Role of ADAMTS-13 Mark Cunningham,MD Director, Hematology Laboratory Department of Pathology University of Kansas Medical Center College of American Pathologists

More information

Approccio morfologico alle microangiopatie trombotiche

Approccio morfologico alle microangiopatie trombotiche Approccio morfologico alle microangiopatie trombotiche Gina Zini Polo Oncologia e Ematologia Policlinico A. Gemelli Università Cattolica S. Cuore - Roma 1 Thrombotic microangiopathies Occlusive microangiopathic

More information

Year 2004 Paper one: Questions supplied by Megan

Year 2004 Paper one: Questions supplied by Megan QUESTION 53 Endothelial cell pathology on renal biopsy is most characteristic of which one of the following diagnoses? A. Pre-eclampsia B. Haemolytic uraemic syndrome C. Lupus nephritis D. Immunoglobulin

More information

Beyond Plasma Exchange: Targeted Therapy for Thrombotic Thrombocytopenic Purpura

Beyond Plasma Exchange: Targeted Therapy for Thrombotic Thrombocytopenic Purpura Beyond Plasma Exchange: Targeted Therapy for Thrombotic Thrombocytopenic Purpura Kristen Knoph, PharmD, BCPS PGY2 Pharmacotherapy Resident Pharmacy Grand Rounds April 25, 2017 2016 MFMER slide-1 Objectives

More information

Hemolytic uremic syndrome: Investigations and management

Hemolytic uremic syndrome: Investigations and management Hemolytic uremic syndrome: Investigations and management SAWAI Toshihiro M.D., Ph.D. Department of Pediatrics, Shiga University of Medical Science Otsu, JAPAN AGENDA TMA; Thrombotic micro angiopathy STEC-HUS;

More information

Thrombotic Microangiopathies (TMA) / TTP/HUS/αHUS Pathology & Molecular. Genetics

Thrombotic Microangiopathies (TMA) / TTP/HUS/αHUS Pathology & Molecular. Genetics Thrombotic Microangiopathies (TMA) / TTP/HUS/αHUS Pathology & Molecular Genetics Helen Liapis, M.D. Senior Consultant Arkana Labs Professor of Pathology & Immunology. retired Washington University School

More information

What is meant by Thrombotic Microangiopathy (TMA)?

What is meant by Thrombotic Microangiopathy (TMA)? What is meant by Thrombotic Microangiopathy (TMA)? Thrombotic Microangiopathy (TMA) is a group of disorders characterized by injured endothelial cells, microangiopathic hemolytic anemia (MAHA), with its

More information

* Renal insufficiencies

* Renal insufficiencies Thrombotic Thrombocytopenic Purpura Behzad Poopak, DCLS PhD. Tehran medical Branch Islamic Azad university bpoopak@yahoo.com Case Summary Ms. X, a 35-year year-old woman Complained of weakness, low grade

More information

A 60 year old woman with altered mental status and thrombotic microangiopathy. Josh Veatch

A 60 year old woman with altered mental status and thrombotic microangiopathy. Josh Veatch A 60 year old woman with altered mental status and thrombotic microangiopathy Josh Veatch Previously healthy 60 year old woman 2 3 months of fatigue following a URI, transient episodes being out of it

More information

Thrombotic Thrombocytopenic

Thrombotic Thrombocytopenic The Treatment of TTP and the Prevention of Relapses GERALD APPEL, MD Professor of Clinical Medicine Columbia University College of Physicians and Surgeons NY-Presbyterian Hospital New York, New York Thrombotic

More information

Bleeding and Thrombotic Disorders. Kristine Krafts, M.D.

Bleeding and Thrombotic Disorders. Kristine Krafts, M.D. Bleeding and Thrombotic Disorders Kristine Krafts, M.D. Bleeding and Thrombotic Disorders Bleeding disorders von Willebrand disease Hemophilia A and B DIC TTP/HUS ITP Thrombotic disorders Factor V Leiden

More information

Thrombotic thrombocytopenic purpura: a look at the future

Thrombotic thrombocytopenic purpura: a look at the future Thrombotic thrombocytopenic purpura: a look at the future Andrea Artoni, MD Ph.D. Angelo Bianchi Bonomi Hemophilia and Thrombosis Center IRCCS Ca Granda Ospedale Maggiore Policlinico Milan, Italy andrea.artoni@policlinico.mi.it

More information

A 36 year old previously healthy female develops fever and ruising

A 36 year old previously healthy female develops fever and ruising Renal vascular diseases CPC G.A. Appel MD M.B. Stokes MD Case 1 A 36 year old previously healthy female develops fever and bruising. She goes to her LMD and CBC shows plats 15 K, Hct 28%, normal PT and

More information

R. Coward has documented that he has received cooperative grants from Takeda and Novo Nordisk

R. Coward has documented that he has received cooperative grants from Takeda and Novo Nordisk R. Coward has documented that he has received cooperative grants from Takeda and Novo Nordisk Advances in our understanding of the pathogenesis of glomerular thrombotic microangiopathy Lindsay Keir Richard

More information

DRUG NAME: Eculizumab Brand(s): Soliris DOSAGE FORM/ STRENGTH: 10 mg/ml (300 mg per vial)

DRUG NAME: Eculizumab Brand(s): Soliris DOSAGE FORM/ STRENGTH: 10 mg/ml (300 mg per vial) Preamble: A confirmed diagnosis of atypical hemolytic uremic syndrome (ahus) is required for eculizumab funding. The information below is to provide clinicians with context for how a diagnosis of ahus

More information

DR V PHILIP CLINICAL HAEMATOLOGY UNIT CHRIS HANI BARAGWANATH ACADEMIC HOSPITAL

DR V PHILIP CLINICAL HAEMATOLOGY UNIT CHRIS HANI BARAGWANATH ACADEMIC HOSPITAL DR V PHILIP CLINICAL HAEMATOLOGY UNIT CHRIS HANI BARAGWANATH ACADEMIC HOSPITAL Rare but fatal disease if unrecognized and untreated Incidence about 1: 1 million in the USA Female preponderance of 2:1 Part

More information

Coagulation Disorders. Dr. Muhammad Shamim Assistant Professor, BMU

Coagulation Disorders. Dr. Muhammad Shamim Assistant Professor, BMU Coagulation Disorders Dr. Muhammad Shamim Assistant Professor, BMU 1 Introduction Local Vs. General Hematoma & Joint bleed Coagulation Skin/Mucosal Petechiae & Purpura PLT wound / surgical bleeding Immediate

More information

Dr. E.SUDHA (Fellow in Pediatric Nephrology) DEPT OF PEDIATRIC NEPHROLOGY & DIALYSIS Dr.MEHTA CHILDRENS HOSPITAL

Dr. E.SUDHA (Fellow in Pediatric Nephrology) DEPT OF PEDIATRIC NEPHROLOGY & DIALYSIS Dr.MEHTA CHILDRENS HOSPITAL Dr. E.SUDHA (Fellow in Pediatric Nephrology) DEPT OF PEDIATRIC NEPHROLOGY & DIALYSIS Dr.MEHTA CHILDRENS HOSPITAL CASE HISTORY 4 yrs old previously well boy Born to 2 nd degree consanguinity Fever x 5 days

More information

Fußzeile (Titel der Präsentation) 1. Thrombotic Microangiopathy: The German Experience 4. Conflictof interest: none

Fußzeile (Titel der Präsentation) 1. Thrombotic Microangiopathy: The German Experience 4. Conflictof interest: none Thrombotic Microangiopathy: The German Experience 3 Nephropathology Section, Institute of Pathology, Hamburg, Germany Agenda 1. Difficulties in the diagnosis TMA 2. Previous efforts to reach consensus

More information

RECURRENT AND DE NOVO RENAL DISEASES IN THE ALLOGRAFT. J. H. Helderman,MD,FACP,FAST

RECURRENT AND DE NOVO RENAL DISEASES IN THE ALLOGRAFT. J. H. Helderman,MD,FACP,FAST RECURRENT AND DE NOVO RENAL DISEASES IN THE ALLOGRAFT J. H. Helderman,MD,FACP,FAST Vanderbilt University Medical Center Professor of Medicine, Pathology and Immunology Medical Director, Vanderbilt Transplant

More information

Let`s go for the diagnosis! Yazeed Toukan, MD Pediatric Pulmonary Institute, Ruth Rappaport Children`s Hospital July 2016

Let`s go for the diagnosis! Yazeed Toukan, MD Pediatric Pulmonary Institute, Ruth Rappaport Children`s Hospital July 2016 Let`s go for the diagnosis! Yazeed Toukan, MD Pediatric Pulmonary Institute, Ruth Rappaport Children`s Hospital July 2016 Case report 20 months old girl Israeli Arab Muslim family, consanguineous marriage

More information

Renal failure and thrombocytopaenia? Don t forget TTP/HUS. Jonathan Wala Nephrologist

Renal failure and thrombocytopaenia? Don t forget TTP/HUS. Jonathan Wala Nephrologist Renal failure and thrombocytopaenia? Don t forget TTP/HUS Jonathan Wala Nephrologist Thrombotic microangiopathies Disorders characterized by: thrombocytopaenia microangiopathic haemolytic anaemia (MAHA)

More information

Objectives. Thrombotic Thrombocytopenic Purpura (TTP) and ADAMTS13 Testing. Disclosure

Objectives. Thrombotic Thrombocytopenic Purpura (TTP) and ADAMTS13 Testing. Disclosure Thrombotic Thrombocytopenic Purpura (TTP) and Testing Dong Chen MD PhD Special Coagulation Laboratory Mayo Clinic-Rochester 2018 Disclosure Chair, CAP Coagulation Resource Committee Mayo Medical Laboratory

More information

AABB 2003 ANNUAL MEETING AWARD LECTURES

AABB 2003 ANNUAL MEETING AWARD LECTURES Blackwell Science, LtdOxford, UKTRFTransfusion0041-11322004 American Association of Blood BanksSeptember 200444913841392Original ArticleTHE OKLAHOMA TTP-HUS REGISTRYGEORGE AABB 2003 ANNUAL MEETING AWARD

More information

Presentation Outline. Disease Background Previous research on platelet recovery rate Goal of our study Methods Results Limitations Conclusions

Presentation Outline. Disease Background Previous research on platelet recovery rate Goal of our study Methods Results Limitations Conclusions Platelet Recovery Rate at Day 5 of Therapeutic Plasma Exchange for Acquired Thrombotic Thrombocytopenic Purpura Can Aid in Identifying Risk of Disease Exacerbation Suzanne Zhou, Yara A. Park, Marian A.

More information

Dr Ian Roberts Oxford

Dr Ian Roberts Oxford Dr Ian Roberts Oxford Oxford Pathology Course 2010 for FRCPath Present the basic diagnostic features of the commonest conditions causing renal failure Highlight diagnostic pitfalls. Crescentic GN: renal

More information

Challenges in Renal Apheresis. Mark E. Williams MD, FACP, FASN Director, Renal Apheresis Beth Israel Deaconess Medical Center Harvard Medical School

Challenges in Renal Apheresis. Mark E. Williams MD, FACP, FASN Director, Renal Apheresis Beth Israel Deaconess Medical Center Harvard Medical School Challenges in Renal Apheresis Mark E. Williams MD, FACP, FASN Director, Renal Apheresis Beth Israel Deaconess Medical Center Harvard Medical School Outline Principles of Separation ASFA Guidelines Renal

More information

Clinical Study Eculizumab Therapy Leads to Rapid Resolution of Thrombocytopenia in Atypical Hemolytic Uremic Syndrome

Clinical Study Eculizumab Therapy Leads to Rapid Resolution of Thrombocytopenia in Atypical Hemolytic Uremic Syndrome Hindawi Publishing Corporation Advances in Hematology Volume 214, Article ID 295323, 7 pages http://dx.doi.org/1.1155/214/295323 Clinical Study Therapy Leads to Rapid Resolution of Thrombocytopenia in

More information

Thrombotic Thrombocytopenic Purpura and ADAMTS-13: New Insights into Pathogenesis, Diagnosis, and Therapy

Thrombotic Thrombocytopenic Purpura and ADAMTS-13: New Insights into Pathogenesis, Diagnosis, and Therapy Thrombotic Thrombocytopenic Purpura and ADAMTS-13: New Insights into Pathogenesis, Diagnosis, and Therapy Janis Wyrick-Glatzel, MS, MT(ASCP) (University of Nevada Las Vegas, Las Vegas, NV) DOI: 10.1309/77KRKLJW0EA75T2R

More information

Primary causes: Complement dysregulation (50% of non-shiga toxin-producing E. coli ) Secondary causes:

Primary causes: Complement dysregulation (50% of non-shiga toxin-producing E. coli ) Secondary causes: General department INTRODUCTION The hemolytic uremic syndrome (HUS): microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney injury One of the main causes of acute kidney injury in children

More information

Risk factors of chronic renal failure after atypical Hemolytic Uremic Syndrome under plasmatherapy

Risk factors of chronic renal failure after atypical Hemolytic Uremic Syndrome under plasmatherapy Risk factors of chronic renal failure after atypical Hemolytic Uremic Syndrome under plasmatherapy Professeur Eric Rondeau Urgences néphrologiques et Transplantation rénale Hôpital Tenon, Paris WWA SFH

More information

Sara K. Vesely, James N. George, Bernhard Lämmle, Jan-Dirk Studt, Lorenzo Alberio, Mayez A. El-Harake, and Gary E. Raskob

Sara K. Vesely, James N. George, Bernhard Lämmle, Jan-Dirk Studt, Lorenzo Alberio, Mayez A. El-Harake, and Gary E. Raskob CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS ADAMTS13 activity in thrombotic thrombocytopenic purpura hemolytic uremic syndrome: relation to presenting features and clinical outcomes in

More information

HEME 10 Bleeding Disorders

HEME 10 Bleeding Disorders HEME 10 Bleeding Disorders When injury occurs, three mechanisms occur Blood vessels Primary hemostasis Secondary hemostasis Diseases of the blood vessels Platelet disorders Thrombocytopenia Functional

More information

TTP, Sickle Cell Disease, and the role of von Willebrand factor

TTP, Sickle Cell Disease, and the role of von Willebrand factor TTP, Sickle Cell Disease, and the role of von Willebrand factor José A. López Puget Sound Blood Center University of Washington Seattle, WA Disclosures No conflicts to disclose. Thrombotic Thrombocytopenic

More information

Oncologic Emergencies. Angelina The, MD Lynn Cancer Institute August 30, 2016

Oncologic Emergencies. Angelina The, MD Lynn Cancer Institute August 30, 2016 Oncologic Emergencies { Angelina The, MD Lynn Cancer Institute August 30, 2016 What constitutes an oncologic emergency? Complications arising from Cancer Paraneoplastic syndrome Treatment of cancer Requires

More information

Platelets: Thrombotic Thrombocytopenic Purpura

Platelets: Thrombotic Thrombocytopenic Purpura Platelets: Thrombotic Thrombocytopenic Purpura James N. George, J. Evan Sadler, and Bernhard Lämmle Abnormalities of plasma von Willebrand factor (VWF) have been recognized to be associated with thrombotic

More information

Pathology note 8 BLEEDING DISORDER

Pathology note 8 BLEEDING DISORDER Pathology note 8 BLEEDING DISORDER Slide75 ( Types of clotting factors deficiency): Today we will talk about public public factor deficiency it could be acquired or inherited, acquired diseases are more

More information

TMA in HUS and TTP: new insights

TMA in HUS and TTP: new insights TMA in HUS and TTP: new insights Daan Dierickx University Hospitals Leuven, Department of Hematology, Belgium 20th Annual Meeting Belgian Society on Thrombosis and Haemostatis Antwerpen, 22 th November

More information

Atypical Hemolytic Uremic Syndrome: When the Environment and Mutations Affect Organ Systems. A Case Report with Review of Literature

Atypical Hemolytic Uremic Syndrome: When the Environment and Mutations Affect Organ Systems. A Case Report with Review of Literature Atypical Hemolytic Uremic Syndrome: When the Environment and Mutations Affect Organ Systems. A Case Report with Review of Literature Mouhanna Abu Ghanimeh 1, Omar Abughanimeh 1, Ayman Qasrawi 1, Abdulraheem

More information

LAMA SHATAT TTP, ITP, DIC

LAMA SHATAT TTP, ITP, DIC TTP, ITP, DIC Reduction in platelet number (thrombocytopenia) constitutes an important cause of generalized bleeding. A count less than 100,000 platelets/μl is generally considered to constitute thrombocytopenia.

More information

Thrombotic thrombocytopenic purpura: 2008 Update

Thrombotic thrombocytopenic purpura: 2008 Update MEDICAL GRAND ROUNDS CME CREDIT MARK A. CROWTHER, MD Director, Division of Hematology, McMaster University, Hamilton, Ontario, Canada JAMES N. GEORGE, MD Hematology-Oncology Section, Department of Medicine,

More information

HUS and TTP Testing. Kenneth D. Friedman, M.D. Director, Hemostasis Reference Lab BloodCenter of Wisconsin, Milwaukee WI

HUS and TTP Testing. Kenneth D. Friedman, M.D. Director, Hemostasis Reference Lab BloodCenter of Wisconsin, Milwaukee WI HUS and TTP Testing Kenneth D. Friedman, M.D. Director, Hemostasis Reference Lab BloodCenter of Wisconsin, Milwaukee WI Disclosures Relevant Financial Relationships Consultant: Ablynx, Bayer, CSL Behring,

More information

A Rational Approach to Evaluation of Thrombotic Microangiopathy

A Rational Approach to Evaluation of Thrombotic Microangiopathy A Rational Approach to Evaluation of Thrombotic Microangiopathy An Algorithmic Approach C. Christopher Hook, MD for the Complement Alternative Pathway Thrombotic Micro- Angiopathy (CAP-TMA) Disease-Oriented

More information

Hemolytic uremic syndrome

Hemolytic uremic syndrome Hemolytic uremic syndrome Doyeun Oh Department of Internal Medicine CHA University School of Medicine Disclosures for Doyeun Oh Research Support/P.I. Employee Consultant Major Stockholder Speakers Bureau

More information

Dr. Rai Muhammad Asghar Associate Professor Head of Pediatric Department Rawalpindi Medical College

Dr. Rai Muhammad Asghar Associate Professor Head of Pediatric Department Rawalpindi Medical College Dr. Rai Muhammad Asghar Associate Professor Head of Pediatric Department Rawalpindi Medical College AN APPROACH TO BLEEDING DISORDERS NORMAL HEMOSTASIS After injury, 3 processes halt bleeding Vasoconstriction

More information

Accepted Manuscript. No more thrombotic thrombocytopenic purpura/hemolytic uremic syndrome please. Yeong-Hau H. Lien MD, PhD S (18)

Accepted Manuscript. No more thrombotic thrombocytopenic purpura/hemolytic uremic syndrome please. Yeong-Hau H. Lien MD, PhD S (18) Accepted Manuscript No more thrombotic thrombocytopenic purpura/hemolytic uremic syndrome please Yeong-Hau H. Lien MD, PhD PII: S0002-9343(18)30965-3 DOI: https://doi.org/10.1016/j.amjmed.2018.10.009 Reference:

More information

Heme (Bleeding and Coagulopathies) in the ICU

Heme (Bleeding and Coagulopathies) in the ICU Heme (Bleeding and Coagulopathies) in the ICU General Topics To Discuss Transfusions DIC Thrombocytopenia Liver and renal disease related bleeding Lack of evidence in managing critical illness related

More information

Soliris (eculizumab) DRUG.00050

Soliris (eculizumab) DRUG.00050 Market DC Soliris (eculizumab) DRUG.00050 Override(s) Prior Authorization Approval Duration 1 year Medications Soliris (eculizumab) APPROVAL CRITERIA Paroxysmal Nocturnal Hemoglobinuria I. Initiation of

More information

Non-immune acquired haemolytic anaemias. Dr.Maysem

Non-immune acquired haemolytic anaemias. Dr.Maysem Non-immune acquired haemolytic anaemias Dr.Maysem Causes of Non-immune acquired haemolytic anaemias. Infections Infections can cause haemolysis in a variety of ways: -They may precipitate an acute haemolytic

More information

Thrombotic microangiopathy and indications for therapeutic plasma exchange

Thrombotic microangiopathy and indications for therapeutic plasma exchange SPIN DOCTORS:APHERESIS FOR HEMATOLOGISTS Thrombotic microangiopathy and indications for therapeutic plasma exchange Jill Adamski 1 1 Department of Laboratory Medicine and Pathology, Mayo Clinic Arizona,

More information

Long-Term Outcomes After Successful Treatment of TTP

Long-Term Outcomes After Successful Treatment of TTP Long-Term Outcomes After Successful Treatment of TTP Spero R. Cataland, M.D. Assoc. Professor of Clinical Internal Medicine Division of Hematology Ohio State University Historical Perspective Prior to

More information

Not So Benign Hematology Aplastic anemia, Paroxysmal Nocturnal Hemoglobinuria, atypical Hemolytic Uremic Syndrome, Thrombotic Thrombocytopenic Purpura

Not So Benign Hematology Aplastic anemia, Paroxysmal Nocturnal Hemoglobinuria, atypical Hemolytic Uremic Syndrome, Thrombotic Thrombocytopenic Purpura Not So Benign Hematology Aplastic anemia, Paroxysmal Nocturnal Hemoglobinuria, atypical Hemolytic Uremic Syndrome, Thrombotic Thrombocytopenic Purpura Robert A. Brodsky, MD Johns Hopkins Family Professor

More information

RECURRENT AND DE NOVO RENAL DISEASES IN THE ALLOGRAFT

RECURRENT AND DE NOVO RENAL DISEASES IN THE ALLOGRAFT RECURRENT AND DE NOVO RENAL DISEASES IN THE ALLOGRAFT HISTOPATHOLOGIC DISORDERS AFFECTING THE ALLOGRAFT OTHER THAN REJECTION RECURRENT DISEASE DE NOVO DISEASE TRANSPLANT GLOMERULOPATHY Glomerular Non-glomerular

More information

Initial management of TMA syndromes

Initial management of TMA syndromes Initial management of TMA syndromes Elie Azoulay, Saint-Louis Hospital, Medical Intensive Care Unit Paris Diderot Sorbonne University Groupe de Recherche Respiratoire en Réanimation Onco-Hématologique

More information

Current understanding of the pathophysiology of thrombotic thrombocytopenic purpura

Current understanding of the pathophysiology of thrombotic thrombocytopenic purpura J Clin Pathol 2000;53:497 501 497 Haemostasis Research Unit, University College Hospital, 98 Chenies Mews, London WC1E 6HX, UK S L Allford S J Machin Correspondence to: Dr Allford email: mach263@msn.com

More information

Thrombotic microangiopathy (TMA) has been considered

Thrombotic microangiopathy (TMA) has been considered Thrombotic Microangiopathy After Allogeneic Hematopoietic Stem Cell Transplantation: An Autopsy Study Koushan Siami, 1 Kiarash Kojouri, 2 Karen K. Swisher, 3 George B. Selby, 2 James N. George, 2 and Zoltan

More information

Haemolytic uraemic syndrome the story of a whodunit

Haemolytic uraemic syndrome the story of a whodunit Haemolytic uraemic syndrome the story of a whodunit Paul Warwicker Lancashire Teaching Hospitals NHS Trust RCP Kidney for the General Physician Conference Nov 17 Renal thrombotic microangiopathy (TMA)

More information

Thrombotic Microangiopathies

Thrombotic Microangiopathies Thrombotic Microangiopathies ASH/San Antonio Breast Cancer Symposium Review James N. George March 14, 2015 Thrombotic Microangiopathies (TMA): Everything you need to know from 5 patient stories Thrombotic

More information

Putting the Pieces Together. Anne Longtine MD Internal Medicine Residency, Maine Medical Center Maine ACP Annual Meeting Clinical Vignette 9/16/2017

Putting the Pieces Together. Anne Longtine MD Internal Medicine Residency, Maine Medical Center Maine ACP Annual Meeting Clinical Vignette 9/16/2017 Putting the Pieces Together Anne Longtine MD Internal Medicine Residency, Maine Medical Center Maine ACP Annual Meeting Clinical Vignette 9/16/2017 One Week Ago: Outpatient Clinic 64 y/o female presenting

More information

THE MULTIPLE FACETS OF THROMBOTIC MICROANGIOPATHIES

THE MULTIPLE FACETS OF THROMBOTIC MICROANGIOPATHIES THE MULTIPLE FACETS OF THROMBOTIC MICROANGIOPATHIES Summary of Presentations from the Alexion-Sponsored Symposium, held at the 19 th EHA Congress, Milan, Italy, on 12 th June 2014 Chairperson Pier Mannuccio

More information

Management of Rejection

Management of Rejection Management of Rejection I have no disclosures Disclosures (relevant or otherwise) Deborah B Adey, MD Professor of Medicine University of California, San Francisco Kidney and Pancreas Transplant Center

More information

SHIGA-TOXIN PRODUCING ESCHERICHIA COLI STEC Update. Roshan Reporter, MD, MPH Rita Bagby, PS-PHN Leticia Martinez, PS-PHN

SHIGA-TOXIN PRODUCING ESCHERICHIA COLI STEC Update. Roshan Reporter, MD, MPH Rita Bagby, PS-PHN Leticia Martinez, PS-PHN SHIGA-TOXIN PRODUCING ESCHERICHIA COLI STEC Update Roshan Reporter, MD, MPH Rita Bagby, PS-PHN Leticia Martinez, PS-PHN Objectives At the conclusion of this presentation the participant should be able

More information

Thrombocytosis. Leukemias Cell Therapies

Thrombocytosis. Leukemias Cell Therapies Clinical Applications of Therapeutic Apheresis Presentation: Prof. A. Pourazar TA Technologies Membrane Prisma Gambro BCT Asahi Plasma Flow Centrifugation Cascade apheresis for selective plasma component

More information

Paolo Gresele Dipartimento di Medicina, Sezione di Medicina Interna e Cardiovascolare, Università di Perugia

Paolo Gresele Dipartimento di Medicina, Sezione di Medicina Interna e Cardiovascolare, Università di Perugia Le sindromi trombotiche microangiopatiche: il ruolo del laboratorio Paolo Gresele Dipartimento di Medicina, Sezione di Medicina Interna e Cardiovascolare, Università di Perugia Microangiopatie trombotiche:

More information

ahus A PATIENT S GUIDE To learn more about ahus, visit Copyright 2011, Alexion Pharmaceuticals, Inc. All rights reserved.

ahus A PATIENT S GUIDE To learn more about ahus, visit  Copyright 2011, Alexion Pharmaceuticals, Inc. All rights reserved. To learn more about ahus, visit www.ahussource.com ahus A PATIENT S GUIDE Copyright 2011, Alexion Pharmaceuticals, Inc. All rights reserved. SOL 1169 BECOME EMPOWERED By learning more and taking control

More information

Untying the Knot of Thrombotic Thrombocytopenic Purpura and Atypical Hemolytic Uremic Syndrome

Untying the Knot of Thrombotic Thrombocytopenic Purpura and Atypical Hemolytic Uremic Syndrome REVIEW Untying the Knot of Thrombotic Thrombocytopenic Purpura and Atypical Hemolytic Uremic Syndrome Han-Mou Tsai, MD imah Hematology Associates, New Hyde Park, NY. ABSTRACT Patients presenting with microangiopathic

More information

Index. Note: Page numbers of article titles are in boldface type.

Index. Note: Page numbers of article titles are in boldface type. Index Note: Page numbers of article titles are in boldface type. A Acute lung injury (ALI) transfusion-related, 363 372. See also Transfusion-related acute lung injury (TRALI) ALI. See Acute lung injury

More information

Cigna Drug and Biologic Coverage Policy

Cigna Drug and Biologic Coverage Policy Cigna Drug and Biologic Coverage Policy Subject Eculizumab Table of Contents Coverage Policy... 1 General Background... 4 Coding/Billing Information... 5 References... 6 Effective Date... 8/15/2018 Next

More information

PLASMA EXCHANGE J MANION NEPEAN HOSPITAL

PLASMA EXCHANGE J MANION NEPEAN HOSPITAL PLASMA EXCHANGE J MANION NEPEAN HOSPITAL PLASMA The fluid portion of blood Normally approx 5% body weight or 3.5L in 70kg male Clots on standing unless anticoagulated Common plasma proteins are albumin,

More information

HUS-MPGN-TTP. & related disorders

HUS-MPGN-TTP. & related disorders ES-PCR 4 th International Conference HUS-MPGN-TTP & related disorders Current diagnosis and therapy of hemolytic uremic syndrome (HUS), membranoproliferative glomerulonephritis (MPGN), thrombotic thrombocytopenic

More information

Thrombotic Thrombocytopenic Purpura From Platelet Aggregates to Plasma

Thrombotic Thrombocytopenic Purpura From Platelet Aggregates to Plasma Pathology Patterns Reviews Thrombotic Thrombocytopenic Purpura From Platelet Aggregates to Plasma Marisa B. Marques, MD, 1 Charles A. Mayfield, MD, PhD, 1 and Douglas P. Blackall, MD 2 Key Words: Thrombotic

More information

Thrombotic microangiopathies and antineoplastic agents

Thrombotic microangiopathies and antineoplastic agents Thrombotic microangiopathies and antineoplastic agents Paul Coppo paul.coppo@aphp.fr Service d Hématologie - Hôpital Saint-Antoine AP-HP et Université Pierre & Marie Curie Centre de Référence des Microangiopathies

More information

RaDaR Inclusion and Exclusion Criteria. Diagnosis Inclusion Criteria Exclusion Criteria. Alport Syndrome definite or probable

RaDaR Inclusion and Exclusion Criteria. Diagnosis Inclusion Criteria Exclusion Criteria. Alport Syndrome definite or probable Alport Syndrome and Type IV collagenopathies APRT Deficiency Alport Syndrome definite or probable Alport carrier definite or probable Thin basement membrane nephropathy APRT Deficiency confirmed Abolished

More information

Thrombotic Microangiopathies, Thrombotic Thrombocytopenic Purpura, and ADAMTS-13

Thrombotic Microangiopathies, Thrombotic Thrombocytopenic Purpura, and ADAMTS-13 47 Thrombotic Microangiopathies, Thrombotic Thrombocytopenic Purpura, and ADAMTS-13 Kent Chapman, B.Sc. (Biomed) 1 Michael Seldon, F.R.A.C.P., F.R.C.P.A., M.B.B.S., B.Sc. (Med) 2 Ross Richards, Ph.D.,

More information

Case Studies. Scleroderma Renal Crisis or Thrombotic Thrombocytopenic Purpura: Seeing Through the Masquerade. Patient 1

Case Studies. Scleroderma Renal Crisis or Thrombotic Thrombocytopenic Purpura: Seeing Through the Masquerade. Patient 1 Scleroderma Renal Crisis or Thrombotic Thrombocytopenic Purpura: Seeing Through the Masquerade Emily Keeler, DO, 1* Gloria Fioravanti, DO, FACP, 1 Bensson Samuel, MD, PG Dip, 1 Santo Longo, MD 2 Lab Med

More information

Haemostasis & Coagulation disorders Objectives:

Haemostasis & Coagulation disorders Objectives: Haematology Lec. 1 د.ميسم مؤيد علوش Haemostasis & Coagulation disorders Objectives: - Define haemostasis and what are the major components involved in haemostasis? - How to assess the coagulation status?

More information

Hemolytic Uremic Syndrome Epidemiological and Clinical Facts

Hemolytic Uremic Syndrome Epidemiological and Clinical Facts THE HEMOLYTIC IRAQI POSTGRADUATE UREMIC MEDICAL SYNDROME JOURNAL Hemolytic Uremic Syndrome Epidemiological and Clinical Facts Najla Ibrahiem Ayoub, Ahmed Hameed Mohammed, Jinan Soaod Orabi, Asaad Abdullah

More information

TTP and ADAMTS13: When Is Testing Appropriate?

TTP and ADAMTS13: When Is Testing Appropriate? TTP and ADAMTS13: When Is Testing Appropriate? Pier Mannuccio Mannucci and Flora Peyvandi A. Bianchi Bonomi Hemophilia and Thrombosis Center, Department of Medicine and Medical Specialities, University

More information

1) unexplained microangiopathic hemolytic anemia (Coombs negative anemia),

1) unexplained microangiopathic hemolytic anemia (Coombs negative anemia), Ravi Sarode, MD Consensus Process The TTP-CC subcommittee developed 7 key questions Sent to the 7 speakers for electronic voting in Yes or No format Will be published in JCA soon Q.1 Untreated TTP carries

More information

Index. electron microscopy, 81 immunofluorescence microscopy, 80 light microscopy, 80 Amyloidosis clinical setting, 185 etiology/pathogenesis,

Index. electron microscopy, 81 immunofluorescence microscopy, 80 light microscopy, 80 Amyloidosis clinical setting, 185 etiology/pathogenesis, A Acute antibody-mediated rejection (Acute AMR) clinical features, 203 clinicopathologic correlations, 206 pathogenesis, 205 206 204 205 light microscopy, 203 204 Acute cellular rejection (ACR) clinical

More information

Microangiopatia trombotica (MAT) e Sindrome emolitico-uremica atipica (SEUa): Basi patogenetiche, inquadramento diagnostico e principi del

Microangiopatia trombotica (MAT) e Sindrome emolitico-uremica atipica (SEUa): Basi patogenetiche, inquadramento diagnostico e principi del Microangiopatia trombotica (MAT) e Sindrome emolitico-uremica atipica (SEUa): Basi patogenetiche, inquadramento diagnostico e principi del trattamento Vincenzo Montinaro U.O. Nefrologia Azienda Ospedaliera

More information

M.Weitz has documented that he has no relevant financial relationships to disclose or conflict of interest to resolve.

M.Weitz has documented that he has no relevant financial relationships to disclose or conflict of interest to resolve. M.Weitz has documented that he has no relevant financial relationships to disclose or conflict of interest to resolve. Prophylactic eculizumab prior to kidney transplantation for atypical hemolytic uremic

More information

Thrombotic Thrombocytopenic Purpura, Moschcowitz Syndrome

Thrombotic Thrombocytopenic Purpura, Moschcowitz Syndrome Clinical Article Moschcowitz Syndrome Thrombotic Thrombocytopenic Purpura, Moschcowitz Syndrome Judit Müller, MD; Judit Czinyéri, MD; Ildikó Sasvári, MD; Miklós Garami, MD; Gábor Kovács, PhD Abstract The

More information

Appendix to Notification Letter for rituximab and eltrombopag dated 20 February 2014

Appendix to Notification Letter for rituximab and eltrombopag dated 20 February 2014 Appendix to Notification Letter for rituximab and eltrombopag dated 20 February 2014 The notification letter which contains details of the decision to widen the restriction criteria for rituximab and eltrombopag

More information

Symposium. Acute Kidney Injury with Thrombocytopenia. Lalitha A V*, Suryanarayana G**, Sumithra S***

Symposium. Acute Kidney Injury with Thrombocytopenia. Lalitha A V*, Suryanarayana G**, Sumithra S*** Symposium Acute Kidney Injury with Thrombocytopenia 10.21304/2018.0502.00372 Lalitha A V*, Suryanarayana G**, Sumithra S*** *Associate Professor, Head,PICU **, Fellow in PICU, *** Assistant Professor,

More information

Not So Benign Hematology. Robert A. Brodsky, MD Johns Hopkins Family Professor of Medicine and Oncology Division Chief Hematology

Not So Benign Hematology. Robert A. Brodsky, MD Johns Hopkins Family Professor of Medicine and Oncology Division Chief Hematology Not So Benign Hematology Robert A. Brodsky, MD Johns Hopkins Family Professor of Medicine and Oncology Division Chief Hematology Disclosures Dr. Brodsky serves as a Scientific Advisory Board member to:

More information

When a patient presents with TMA, identify the underlying cause for the appropriate diagnosis... IS IT TTP OR IS IT ahus?

When a patient presents with TMA, identify the underlying cause for the appropriate diagnosis... IS IT TTP OR IS IT ahus? When a patient presents with TMA, identify the underlying cause for the appropriate diagnosis... IS IT TTP OR IS IT ahus? ADAMTS13 activity >5% RULES OUT a diagnosis of severe ADAMTS13 deficiency (TTP)

More information

Index. Note: Page numbers of article titles are in boldface type.

Index. Note: Page numbers of article titles are in boldface type. Note: Page numbers of article titles are in boldface type. A Abdominal tumors, in children, 530 531 Alkalinization, in tumor lysis syndrome, 516 Allopurinol, in tumor lysis syndrome, 515 Anaphylaxis, drug

More information

1. INSTRUCTIONS 2. DEFINITION OF HUS

1. INSTRUCTIONS 2. DEFINITION OF HUS CQ_IBK_aHUS_01 / version 25/11/09 European Paediatric Research Group for HUS and related disorders Case questionnaire for diarrhoea negative/vtec (STEC) negative cases acute phase 1. INSTRUCTIONS Please

More information

Cover Page. The handle holds various files of this Leiden University dissertation.

Cover Page. The handle   holds various files of this Leiden University dissertation. Cover Page The handle http://hdl.handle.net/1887/20119 holds various files of this Leiden University dissertation. Author: Lotta, Luca Andrea Title: Pathophysiology of thrombotic thrombocytopenic purpura

More information

Medical Policy. MP Eculizumab (Soliris) Related Policies None. Last Review: 01/24/2019 Effective Date: 04/25/2019 Section: Prescription Drug

Medical Policy. MP Eculizumab (Soliris) Related Policies None. Last Review: 01/24/2019 Effective Date: 04/25/2019 Section: Prescription Drug Medical Policy Last Review: 01/24/2019 Effective Date: 04/25/2019 Section: Prescription Drug Related Policies None DISCLAIMER Our medical policies are designed for informational purposes only and are not

More information

Renal Disease. Please refer to the assignment page Three online modules TBLs

Renal Disease. Please refer to the assignment page Three online modules TBLs Renal Disease Please refer to the assignment page Three online modules TBLs 1 Renal Embryology 2 Lab Tests UA CBC Enzymes Creatinine Creatinine clearance Ammonia Abs C Bx 3 BUN Creatinine Creatinine Clearance

More information

Renal transplantation in adults with thrombotic thrombocv topenic purpura/ haemoly tic-uraemic syndrome

Renal transplantation in adults with thrombotic thrombocv topenic purpura/ haemoly tic-uraemic syndrome Nephrol Dial Transplant (1996) 11: 1810-1814 Original Article Nephrology Dialysis Transplantation Renal transplantation in adults with thrombotic thrombocv topenic purpura/ haemoly tic-uraemic syndrome

More information

Thrombocytopenia is not mandatory to diagnose haemolytic and uremic syndrome

Thrombocytopenia is not mandatory to diagnose haemolytic and uremic syndrome Sallée et al. BMC Nephrology 2013, 14:3 RESEARCH ARTICLE Open Access Thrombocytopenia is not mandatory to diagnose haemolytic and uremic syndrome Marion Sallée 1, Khalil Ismail 1, Fadi Fakhouri 2, Henri

More information

Clinical Presentation and Follow-up of Eighteen Patients with Thrombotic Thrombocytopenic Purpura Received in: March 2007 Accepted in: 14/1/2010

Clinical Presentation and Follow-up of Eighteen Patients with Thrombotic Thrombocytopenic Purpura Received in: March 2007 Accepted in: 14/1/2010 Clinical Presentation and Follow-up of Eighteen Patients with Thrombotic Thrombocytopenic Purpura Received in: March 2007 Accepted in: 14/1/2010 Dr. Ahmed Khudair Yaseen Elmeshhedany * Dr. Ahmed Abdulmajeed

More information

Results of the TITAN study for Caplacizumab

Results of the TITAN study for Caplacizumab Results of the TITAN study for Webcast presentation 17th June 2014 Nanobodies - Inspired by nature Forward looking statements Certain statements, beliefs and opinions in this presentation are forward-looking,

More information

C3 Glomerulopathy. Jun-Ki Park

C3 Glomerulopathy. Jun-Ki Park C3 Glomerulopathy Jun-Ki Park 03.08.11 For the last 30 years classification MPGN is based on glomerular findings by light microscopy with further specification on EM and staining for Ig and complement

More information